Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds.
J Pediatric Infect Dis Soc
; 12(4): 234-238, 2023 Apr 28.
Article
in En
| MEDLINE
| ID: mdl-36929216
Full text:
1
Collection:
01-internacional
Health context:
1_ASSA2030
/
2_ODS3
/
4_TD
Database:
MEDLINE
Main subject:
COVID-19
/
BNT162 Vaccine
Limits:
Humans
Language:
En
Journal:
J Pediatric Infect Dis Soc
Year:
2023
Document type:
Article